Structure and Function of the Non-Structural Protein of Dengue Virus and its Applications in Antiviral Therapy
Dengue fever, a type of global and tropical infectious disease, and its prevention has become a challenging issue worldwide. Antibody-dependent enhancement effects and the virus pathogenic mechanism have not yet been fully elucidated, hindering the development of dengue fever prevention and suitable drug treatment. There is currently no specific prevention and therapy in clinical trials, however, in recent years, studies have focused on the pathogenesis and treatment of dengue. Research focusing on dengue virus nonstructural protein in special drugs for the prevention and control of dengue fever is a new progress leading to improved understanding regarding the prevention and control of dengue fever and suitable drugs for the treatment. The main challenges regarding the structure of dengue virus nonstructural protein and the drugs for antiviral therapy are summarized in this paper..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Current topics in medicinal chemistry - 17(2017), 3, Seite 371-380 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qian Xie [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1989809758 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1989809758 | ||
| 003 | DE-627 | ||
| 005 | 20230515132330.0 | ||
| 007 | tu | ||
| 008 | 170207s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20170206 |
| 035 | |a (DE-627)OLC1989809758 | ||
| 035 | |a (DE-599)GBVOLC1989809758 | ||
| 035 | |a (PRQ)b1547-def0d60344494b3210ce37e7a6a902e19d90f20d2099ca357df2ac101981b0260 | ||
| 035 | |a (KEY)0446467220170000017000300371structureandfunctionofthenonstructuralproteinofden | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q DNB |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 0 | |a Qian Xie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Structure and Function of the Non-Structural Protein of Dengue Virus and its Applications in Antiviral Therapy |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Dengue fever, a type of global and tropical infectious disease, and its prevention has become a challenging issue worldwide. Antibody-dependent enhancement effects and the virus pathogenic mechanism have not yet been fully elucidated, hindering the development of dengue fever prevention and suitable drug treatment. There is currently no specific prevention and therapy in clinical trials, however, in recent years, studies have focused on the pathogenesis and treatment of dengue. Research focusing on dengue virus nonstructural protein in special drugs for the prevention and control of dengue fever is a new progress leading to improved understanding regarding the prevention and control of dengue fever and suitable drugs for the treatment. The main challenges regarding the structure of dengue virus nonstructural protein and the drugs for antiviral therapy are summarized in this paper. | ||
| 700 | 0 | |a Bao Zhang |4 oth | |
| 700 | 0 | |a JianHai Yu |4 oth | |
| 700 | 0 | |a Qinghua Wu |4 oth | |
| 700 | 0 | |a Fangji Yang |4 oth | |
| 700 | 0 | |a Hong Cao |4 oth | |
| 700 | 0 | |a Wei Zhao |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Current topics in medicinal chemistry |d Hilversum [u.a.] : Bentham Science Publ., 2001 |g 17(2017), 3, Seite 371-380 |w (DE-627)338770283 |w (DE-600)2064823-6 |w (DE-576)435515160 |x 1568-0266 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2017 |g number:3 |g pages:371-380 |
| 856 | 4 | 2 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1568-0266&volume=17&issue=3&spage=371 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 17 |j 2017 |e 3 |h 371-380 | ||